Rhythm Pharmaceuticals, Inc. (RYTM) has a negative trailing P/E of -29.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 30.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.38%, forward earnings yield 3.24%. PEG 0.32 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 49/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -19.4 | -0.46 | 68.78 | 0.00 | - |
| 2017 | -23.0 | 1.23 | 5.36 | 0.00 | - |
| 2018 | -11.3 | -0.13 | 3.38 | 0.00 | - |
| 2019 | -6.2 | -0.11 | 2.98 | 0.00 | - |
| 2020 | -10.0 | 0.50 | 7.88 | 0.00 | - |
| 2021 | -7.1 | 0.13 | 1.74 | 156.95 | - |
| 2022 | -8.4 | -0.05 | 5.74 | 64.21 | - |
| 2023 | -14.4 | 1.63 | 15.62 | 34.24 | - |
| 2024 | -13.1 | -0.37 | 20.75 | 26.24 | 0.12% |
| 2025 | -35.4 | 1.25 | 50.02 | 36.66 | 0.08% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.55 | $0.00 | $-25.87M | - |
| 2017 | $-2.54 | $0.00 | $-33.71M | - |
| 2018 | $-2.39 | $0.00 | $-74.06M | - |
| 2019 | $-3.70 | $0.00 | $-134.62M | - |
| 2020 | $-2.96 | $0.00 | $-130.73M | - |
| 2021 | $-1.37 | $3.15M | $-68.01M | -2156.2% |
| 2022 | $-3.51 | $23.64M | $-183.08M | -774.5% |
| 2023 | $-3.20 | $77.43M | $-184.68M | -238.5% |
| 2024 | $-4.21 | $130.13M | $-260.6M | -200.3% |
| 2025 | $-3.11 | $189.76M | $-196.54M | -103.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.08 | $-4.01 – $-0.77 | $288.02M | $245.42M – $361.36M | 12 |
| 2027 | $-0.44 | $-25.76 – $21.24 | $537.14M | $315.21M – $666.14M | 11 |
| 2028 | $2.82 | $0.10 – $6.16 | $871.44M | $871.41M – $871.47M | 9 |
| 2029 | $6.74 | $4.66 – $8.39 | $1.3B | $994.77M – $1.55B | 3 |
| 2030 | $10.85 | $7.51 – $13.52 | $1.81B | $1.38B – $2.15B | 3 |
